Avalglucosidase Alfa — Drug Intelligence | 5 EU Trials

Filter these 5 trials by condition, phase, country and more.

5 Registered trials

3 Recruiting

2 Completed trials

4 Sponsors

7 Countries

Phase III

Phase IV

Phase III: 1 Phase IV: 4

Indications tested

5 total

Treatment frequency Reduction In POmpe disease (TRIPO-Study) Recruiting

2024-514255-15-01 Phase IV 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Safety and efficacy of avalglucosidase alfa in patients with non-classic Pompe disease aged ≥ 5 years. Recruiting

2024-518215-18-00 Phase IV 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
GLYCOGEN RESPONSE TO ENZYME REPLACEMENT THERAPY IN POMPE DISEASE Recruiting

2023-508000-37-01 Phase IV 1 country Rigshospitalet
Avalglucosidase alfa French post-trial access for participants with Pompe disease Ended

2024-514773-22-00 Phase IV 1 country Sanofi Winthrop Industrie
Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa Ended

2024-513859-33-00 Phase III 5 countries Sanofi-Aventis Recherche & Developpement

Showing 1–5 of 5 trials